Adverum Biotechnologies, Inc. Company Review & Valuation

ADVM
Nasdaq
Latest Price
1.65USD
Market Capitalization
161.95mUSD

About Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases.

It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products.

The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage.

It has collaboration agreement with Editas Medicine, Inc.

to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc.

for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis.

The company was formerly known as Avalanche Biotechnologies, Inc.

and changed its name to Adverum Biotechnologies, Inc.

in May 2016.

Adverum Biotechnologies, Inc.

was founded in 2006 and is headquartered in Menlo Park, California.

Industry
Biotechnology
HQ Location
Menlo Park, California

Stock Price

Price data not available for Adverum Biotechnologies, Inc..

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2022 Valuu Analytics Sàrl